# Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery

> **NCT00086866** · PHASE2 · UNKNOWN · sponsor: **European Organisation for Research and Treatment of Cancer - EORTC** · enrollment: 165 (actual)

## Conditions studied

- Melanoma (Skin)

## Interventions

- **BIOLOGICAL:** D1/3-MAGE-3-His fusion protein
- **BIOLOGICAL:** SB-AS02B adjuvant
- **BIOLOGICAL:** SB-AS15 adjuvant

## Key facts

- **NCT ID:** NCT00086866
- **Lead sponsor:** European Organisation for Research and Treatment of Cancer - EORTC
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2004-05
- **Primary completion:** 2007-01
- **Final completion:** —
- **Target enrollment:** 165 (ACTUAL)
- **Last updated:** 2015-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00086866

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00086866, "Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT00086866. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*